Peter Bjodstrup Jensen
Overview
Explore the profile of Peter Bjodstrup Jensen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
419
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Eworuke E, Shinde M, Hou L, Paterson J, Jensen P, Maro J, et al.
Pharmacoepidemiol Drug Saf
. 2024 Sep;
33(9):e5849.
PMID: 39289955
Background: Following the mass recall of valsartan products with nitrosamine impurities in July 2018, the number of patients exposed to these products, the duration of exposure, and the potential for...
2.
Rasmussen L, Jensen P, Reutfors J, Furu K, Skurtveit S, Selmer R, et al.
Eur Child Adolesc Psychiatry
. 2024 Apr;
34(1):159-167.
PMID: 38683400
The aim of this study was to examine variations in use of antidepressants among children and adolescents in the three Scandinavian countries (Sweden, Norway, and Denmark). We identified new users...
3.
Herskind K, Jensen P, Vinter C, Krebs L, Eskildsen L, Broe A, et al.
Clin Epidemiol
. 2024 Feb;
16:121-130.
PMID: 38404706
Purpose: This study aimed to systematically evaluate the validity of variables related to pregnancy, delivery, and key characteristics of the infant in the Danish National Patient Register using maternal medical...
4.
Ladebo L, Rasmussen L, Jensen P, Lindahl M, Ovrehus A, Hallas J, et al.
Pharmacoepidemiol Drug Saf
. 2023 Sep;
33(1):e5700.
PMID: 37743261
Purpose: To describe utilization patterns, characteristics of users and prescribers of the new oral antiviral medication, molnupiravir, indicated for mild-to-moderate COVID-19. Methods: Using nationwide registries, we identified all Danish adults...
5.
Eworuke E, Shinde M, Hou L, Paterson M, Jensen P, Maro J, et al.
BMJ Open
. 2023 Apr;
13(4):e070985.
PMID: 37068898
Objectives: To examine valsartan, losartan and irbesartan usage and switching patterns in the USA, UK, Canada and Denmark before and after July 2018, when the first Angiotensin-Receptor-Blocker (ARB) (valsartan) was...
6.
Reilev M, Jensen P, Ranch L, Egeberg A, Furu K, Gembert K, et al.
BMJ Open
. 2023 Feb;
13(2):e066057.
PMID: 36725094
Introduction: Safe and effective pharmacological treatment is of paramount importance for treating severe psoriasis. Brodalumab, a monoclonal antibody against interleukin (IL) 17 receptor A, was granted marketing authorisation in the...
7.
Bliddal M, Rasmussen L, Andersen J, Jensen P, Pottegard A, Munk-Olsen T, et al.
JAMA Psychiatry
. 2022 Dec;
80(2):176-180.
PMID: 36515919
Importance: The direct and indirect implications of the COVID-19 pandemic have been associated with the mental health of children and adolescents, but it is uncertain whether these implications have been...
8.
Kristensen K, Lund L, Jensen P, Broe A, Rotbain E, Damkier P, et al.
Clin Epidemiol
. 2022 May;
14:567-579.
PMID: 35509520
Purpose: To develop the Nordic Multimorbidity Index (NMI), a multimorbidity measure specifically suited to the Nordic health and administrative registry data based on current diagnosis, treatment, and coding practices. Methods:...
9.
Kildegaard H, Ladebo L, Andersen J, Jensen P, Rasmussen L, Damkier P, et al.
JAMA Intern Med
. 2022 Apr;
182(6):684-686.
PMID: 35467699
No abstract available.
10.
Wesselhoeft R, Rasmussen L, Jensen P, Jennum P, Skurtveit S, Hartz I, et al.
Acta Psychiatr Scand
. 2021 May;
144(2):100-112.
PMID: 34021908
Background: Hypnotic use in children and adolescents is controversial. Objective: To describe the use of hypnotic drugs (melatonin, z-drugs, and sedating antihistamines) among 5- to 24-year-old Scandinavians during 2012 to...